Key result
Yojinkodakuto yields a ~59% eGFR increase in a single advanced CKD case report.
Why the study?
Does Yojinkodakuto improve renal function in a patient with severe chronic kidney disease (stage G4)?
Case Report (n=1)
No
Does Yojinkodakuto improve renal function in a patient with severe chronic kidney disease (stage G4)?
Answers are grounded in this paper and cite their sources.
Yojinkodakuto, a Kampo medicine, may improve renal function and delay the need for dialysis in patients with severe chronic kidney disease (stage G4).
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Hirana et al. (2023) conducted a case report in Chronic Kidney Disease Stage G4 (n=1). Yojinkodakuto was evaluated on Estimated glomerular filtration rate (eGFR). Treatment with Yojinkodakuto over 3 years improved renal function in a patient with stage G4 chronic kidney disease, increasing eGFR from 16 to 25.4 mL/min/1.73 m2.
Synapse has enriched 10 related papers. Consider them for comparative context: